The effect of empagliflozin on P wave peak time and other P wave parameters in patients with diabetes mellitus.
P wave peak time
diabetes mellitus
electrocardiography
empagliflozin
Journal
Pacing and clinical electrophysiology : PACE
ISSN: 1540-8159
Titre abrégé: Pacing Clin Electrophysiol
Pays: United States
ID NLM: 7803944
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
revised:
26
01
2022
received:
24
12
2021
accepted:
06
02
2022
pubmed:
18
2
2022
medline:
22
4
2022
entrez:
17
2
2022
Statut:
ppublish
Résumé
Empagliflozin is a selective SGLT2 inhibitor and provides a significant reduction in hospitalizations in heart failure patients and a reduction in combined cardiovascular deaths regardless of diabetes. The mechanisms of favorable effects remain unclear. Improvement in left ventricular diastolic function and a decrease in filling pressure are any mechanisms of positive effects. These effects may show themselves with some changes on the electrocardiography (ECG). So, we aimed to evaluate the effect of empagliflozin on P wave parameters in type 2 diabetes mellitus patients without HF. Fifty-three patients were included in the study. The electrocardiographic and echocardiographic evaluations were examined at the baseline and end of the third month for all patients. The median age of all patients was 55 (45-64 IQR). After treatment, LA volume (p <.001) and diameter (p = .001) in both the parasternal long-axis (p = .001) and the apical four-chamber view decreased. E/e' and systolic pulmonary arterial pressure were significantly decreased after treatment. P wave duration max,min, PWDmin, and PWdis were significantly shorter after treatment. The P wave peak time (PWPT) in lead D We found shortening of PWPT, PWdis, and PWD as reflections of improvements in left atrial volume and LV diastolic function on ECG after empagliflozin treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Empagliflozin is a selective SGLT2 inhibitor and provides a significant reduction in hospitalizations in heart failure patients and a reduction in combined cardiovascular deaths regardless of diabetes. The mechanisms of favorable effects remain unclear. Improvement in left ventricular diastolic function and a decrease in filling pressure are any mechanisms of positive effects. These effects may show themselves with some changes on the electrocardiography (ECG). So, we aimed to evaluate the effect of empagliflozin on P wave parameters in type 2 diabetes mellitus patients without HF.
METHOD
METHODS
Fifty-three patients were included in the study. The electrocardiographic and echocardiographic evaluations were examined at the baseline and end of the third month for all patients.
RESULTS
RESULTS
The median age of all patients was 55 (45-64 IQR). After treatment, LA volume (p <.001) and diameter (p = .001) in both the parasternal long-axis (p = .001) and the apical four-chamber view decreased. E/e' and systolic pulmonary arterial pressure were significantly decreased after treatment. P wave duration max,min, PWDmin, and PWdis were significantly shorter after treatment. The P wave peak time (PWPT) in lead D
CONCLUSION
CONCLUSIONS
We found shortening of PWPT, PWdis, and PWD as reflections of improvements in left atrial volume and LV diastolic function on ECG after empagliflozin treatment.
Substances chimiques
Benzhydryl Compounds
0
Glucosides
0
Sodium-Glucose Transporter 2 Inhibitors
0
empagliflozin
HDC1R2M35U
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
323-329Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332:73-78.
Inzucchi SE, Bergenstal RM, Buse JB. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-1379.
Ryden L, Grant PJ, Anker SD. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34:3035-3087.
Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012;14:83-90.
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128.
Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451-1461.
Jensen J, Omar M, Kistorp C, et al. Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF). Trials. 2019;20:1-8.
Pabel S, Wagner S, Bollenberg H, et al. Empagliflozin directly improves diastolic function in human heart failure. Eur J Heart Fail. 2018;20:1690-1700.
Lee M, Brooksbank K, Wetherall K, et al. Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation. 2021;143:516-525. https://doi/org/10.1161/CIRCULATIONAHA.120.052186.
Verma S, Rawat S, Ho KL, et al. Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors. JACC Basic Transl Sci. 2018;3:575-587.
Lee HC, Shiou YL, Jhuo SJ, et al. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats. Cardiovasc Diabetol. 2019;18:45.
Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, et al. Empagliflozin ameliorates diastolic dysfunction and left ventricular fibrosis/stiffness in nondiabetic heart failure: a multimodality study. JACC Cardiovasc Imaging. 2021;14:393-407.
Tsai WC, Lee KT, Wu MT, et al. Significant correlation of P-wave parameters with left atrial volume index and left ventricular diastolic function. Am J Med Sci. 2013;346:45-51. https://doi.org/10.1097/MAJ.0b013e318265d8f7. PMID: 23103437.
Burak C, Çağdaş M, Rencüzoğulları I, et al. Association of P wave peak time with left ventricular end-diastolic pressure in patients with hypertension. J Clin Hypertens. 2019;21:608-615.
Yıldırım E, Günay N, Bayam E, Keskin M, Ozturkeri B, Selcuk M. Relationship between paroxysmal atrial fibrillation and a novel electrocardiographic parameter P wave peak time. J Electrocardiol. 2019;57:81-86. https://doi.org/10.1016/j.jelectrocard.2019.09.006.
Huang Z, Zheng Z, Wu B, et al. Predictive value of P wave terminal force in lead V1 for atrial fibrillation: a meta-analysis. Ann Noninvasive Electrocardiol. 2020;25:e12739.
Mcllwain EF, American Society of Echocardiography. Precision and the ASE the ASE guidelines. J Am Soc Echocardiogr. 2013;26:A17. https://doi.org/10.1016/J.echo.2013.10.004.
Fontes-Carvalho R, Ladeiras-Lopes R, Bettencourt P, Leite-Moreira A, Azevedo A. Diastolic dysfunction in the diabetic continuum: association with insulin resistance, metabolic syndrome and type 2 diabetes. Cardiovasc Diabetol. 2015;14:1-9.
Seo JM, Park TH, Lee DY, et al. Subclinical myocardial dysfunction in metabolic syndrome patients without hypertension. J Cardiovasc Ultrasound. 2011;19:134-139.
Stahrenberg R, Edelmann F, Mende M, et al. Association of glucose metabolism with diastolic function along the diabetic continuum. Diabetologia. 2010;53:1331-1340.
Zabalgoitia M, Ismaeil MF, Anderson L, Maklady FA. Prevalence of diastolic dysfunction in normotensive, asymptomatic patients with well-controlled type 2 diabetes mellitus. Am J Cardiol. 2001;87:320-323.
Galderisi M. Diastolic dysfunction and diabetic cardiomyopathy: evaluation by Doppler echocardiography. J Am Coll Cardiol. 2006;48:1548-1551.
From AM, Scott CG, Chen HH. Changes in diastolic dysfunction in diabetes mellitus over time. Am J Cardiol. 2009;103:1463-1466.
Russo C, Jin Z, Homma S, et al. Effect of obesity and overweight on left ventricular diastolic function: a community-based study in an elderly cohort. J Am Coll Cardiol. 2011;57:1368-1374.
Arques S, Roux E, Luccioni R. Current clinical applications of spectral tissue Doppler echocardiography (E/E’ ratio) as a noninvasive surrogate for left ventricular diastolic pressures in the diagnosis of heart failure with preserved left ventricular systolic function. Cardiovasc Ultrasound. 2007;5:16-28.
Verma S, Garg A, Yan AT, et al. Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial. Diabetes Care. 2016;39:e212-e213.
Lan NS, Yeap BB, Fegan PG, Green G, Rankin JM, Dwivedi G. Empagliflozin and left ventricular diastolic function following an acute coronary syndrome in patients with type 2 diabetes. Int J Cardiovasc Imaging. 2021;37:517-527.
Hammoudi N, Jeong D, Singh R, et al. Empagliflozin improves left ventricular diastolic dysfunction in a genetic model of type 2 diabetes. Cardiovasc Drugs Ther. 2017;31:233-246.
Chang HC, Cheng HM. P wave peak time: a time window to evaluate left ventricular diastolic function. J Clin Hypertens. 2019;21:616-617.
Yıldız İ, Yildiz PÖ, Burak C, et al. P wave peak time for predicting an increased left atrial volume index in hemodialysis patients. Med Princ Pract. 2020;29:262-269.
Gunduz H, Binak E, Arinc H, et al. The relationship between P wave dispersion and diastolic dysfunction. Tex Heart Inst J. 2005;32:163.
Kim DH, Kim GC, Kim SH, et al. The relationship between the left atrial volume and the maximum P-wave and P-wave dispersion in patients with congestive heart failure. Yonsei Med J. 2007;48:810-817.
Gudul NE, Karabag T, Sayin MR, Bayraktaroglu T, Aydin M. Atrial conduction times and left atrial mechanical functions and their relation with diastolic function in prediabetic patients. Korean J Intern Med. 2017;32:286.
Movahed MR, Hashemzadeh M, Jamal MM. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol. 2005;105:315-318.
Tsang TS, Barnes ME, Bailey KR, et al. Left atrial volume: important risk marker of incident atrial fibrillation in older men and women. Mayo Clin Proc. 2001;76:467-475.
Ozersari S, Ünal B, Kemal Çabuk A, et al. The prognostic value of P-wave dispersion and left atrial functions assessed with three-dimensional echocardiography in patients with cirrhosis. Eur J Gastroenterol Hepatol. 2020;33:1441-1450.
Sato T, Aizawa Y, Yuasa S, Fujita S, Ikeda Y, Okabe M. The effect of dapagliflozin treatment on epicardial adipose tissue volume and P-wave indices: an ad-hoc analysis of the previous randomized clinical trial. J Atheroscler Thromb. 2020;27:1348-1358.
Nalliah CJ, Sanders P, Kottkamp H, Kalman JM. The role of obesity in atrial fibrillation. Eur Heart J. 2016;37:1565-1572.
Russo V, Ammendola E, De Crescenzo I, Docimo L, Santangelo L, Calabrò R. Severe obesity and P-wave dispersion: the effect of surgically induced weight loss. Obes Surg. 2008;18:90-96.
Ibisoglu E, Boyraz B, Güneş ST, et al. Impact of surgical weight loss on novel P-wave-related variables which are nominated as predictors of atrial arrhythmias. Pacing Clin Electrophysiol. 2021;44:1516-1522.